Crossmark

An immunoassay that distinguishes real neuromyelitis optica signals from a labeling detected in patients receiving natalizumab

Crossref DOI link: https://doi.org/10.1186/1471-2377-14-139

Published: 2014-12

Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY

Authors

Sánchez Gomar, Ismael

Díaz Sánchez, María

Uclés Sánchez, Antonio José

Casado Chocán, José Luis

Ramírez-Lorca, Reposo

Serna, Ana

Villadiego, Javier

Toledo-Aral, Juan José

Echevarría, Miriam
License Information

unspecified valid from 2014-07-01